Share Data
25/06/2024
Brii Biosciences Limited (“Brii Bio”, or the “Company”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide.
Share Graph
| Currency | HKD |
| Previous Close | 1.07 |
| Change (%) | 1.90 |
| Volume | 828,000 |
| Number of Shares(mil) | 729.85 |
| Share Market Cap (mil) | 780.94 |
Pipeline
| Indication | Program | Preclinical | IND | Phase 1 | Phase 2 | Phase 3 | NDA/BLA | Regulatory Authority | Brii Rights | Licensing Partners/Internally Discovered |
|---|---|---|---|---|---|---|---|---|---|---|
|
Infectious Disease Programs |
||||||||||
|
Hepatitis B |
BRII-179 (VBI-2601)/BRII-835 (VIR-2218) Combination |
|
NMPA | Greater China |  |
|||||
|
BRII-179 (VBI-2601)/PEG-IFN-α Combination |
|
NMPA | Greater China |  |
||||||
|
BRII-877 (VIR-3434)(1) |
|
NMPA | Greater China |  |
||||||
|
COVID-19 |
Amubarvimab/romlusevimab Combination(2) (previously BRII-196/BRII-198) |
China BLA approved and commercial launched
|
NMPA/FDA | Global |  |
|||||
|
Under US EUA review
|
|
|||||||||
|
HIV infection |
||||||||||
|
BRII-732(3) |
|
FDA | Global | Internally discovered | ||||||
|
MDR/XDR gram-negative infections |
BRII-636(4)(OMNIvance®) |
|
FDA | Greater China |  |
|||||
|
BRII-672(4)(ORAvanceTM) |
|
FDA | Greater China | |
||||||
|
BRII-693(4)(QPX-9003) |
|
FDA | Greater China | |
||||||
|
Nontuberculosis mycobacteria |
BRII-658(4)(Epetraborole) |
|
FDA | Greater China |  |
|||||
|
Central Nervous System Disease Programs |
||||||||||
|
PPD |
BRII-296 |
|
FDA | Global | Internally discovered | |||||
|
PPD prevention |
BRII-296 |
|
FDA | Global | Internally discovered | |||||
|
Anxiety & Depressive disorder |
BRII-297 |
|
FDA | Global | Internally discovered | |||||
|
Source: Company information Notes: 1. The Phase 2 clinical trials have been conducted by VIR. 2. The filing of EUA application with FDA for combination amubarvimab/romlusevimab has been completed in December 2021. 3. Phase 1 study of BRII-732 is currently on clinical hold as part of FDA’s decision to temporarily hold islatravir-based clinical studies. 4. To this date, the development and clinical trials have been conducted by Qpex and AN2, respectively. |
||||||||||
Board of Directors
|
Audit and Risk Committee |
Nomination Committee |
Remuneration Committee |
Strategic Committee |
Executive Directors |
Non-executive Directors |
Independent Non-executive Directors |
|
|---|---|---|---|---|---|---|---|
|
Dr. Zhi HONG |
|
|
|||||
|
Dr. Ankang LI |
|
|
|||||
|
Mr. Robert Taylor NELSEN |
|
|
|||||
|
Dr. Martin J MURPHY JR |
|
|
|
||||
|
Ms. Grace Hui TANG |
|
|
|
||||
|
Mr. Yiu Wa Alec TSUI |
|
|
|
||||
|
Mr. Gregg Huber ALTON |
|
|
|
||||
|
Dr. Taiyin YANG |
|||||||
| = Chairperson = Member | |||||||
Corporate Executive Team
Susannah Cantrell, Ph.D.
Chief Business Officer
 de Groot, Ph.D..jpg)
Eleanor (Ellee) de Groot, Ph.D.
Chief Technology Officer
Zhi Hong, Ph.D.
Executive Director,
Chairman of the Board and Chief Executive Officer
Ankang Li, Ph.D., J.D., CFA
Chief Strategy and Financial Officer,
Chief Executive Officer of TSB Therapeutics
Rico Liang
General Manager,
Greater China
David Margolis, M.D., MPH
Head of Infectious Diseases Therapy Area
Karen D. Neuendorff
Chief People Officer and Head of Human Resources
Aleksandar Skuban, M.D.
Head of CNS Diseases Therapy Area
Coy Stout
Head of Patient Advocacy
Lianhong Xu, Ph.D.
Head of Discovery
Li Yan, M.D., Ph.D.
Chief Medical Officer
Qing Zhu, Ph.D.
Head of China R&D
Financial Highlights
| BRII-B (RMB'000) | 2020 | 2021 | 2022 |
|---|---|---|---|
| Operating Results | |||
| Other income | 84,625 | 99,032 | 107,857 |
| Other gains and losses | (21,993) | 45,062 | (12,289) |
| Research and development expenses | (875,795) | (494,615) | (440,634) |
| Administrative expenses | (103,396) | (208,404) | (168,629) |
| Fair value loss on financial liabilities at FVTPL | (350,372) | (3,598,847) | - |
| Finance costs | (1,668) | (1,175) | (851) |
| Listing expenses | (14,911) | (32,137) | - |
| Loss for the year | (1,283,510) | (4,191,084) | (489,781) |
| Financial Position | |||
| Total assets | 1,267,944 | 3,611,699 | 3,391,849 |
| Total liabilities | 3,010,646 | 300,443 | 234,352 |
| Total equity (deficits) | (1,742,702) | 3,311,256 | 3,157,497 |
| Selected Items from Consolidated Cash Flow Statement | |||
| Net cash used in operating activities | (403,716) | (879,457) | (496,279) |
| Net cash used in investing activities | (43,650) | (475,756) | (1,433,168) |
| Net cash from financing activities | 657,001 | 3,230,134 | (3,042) |
| Net increase in cash and cash equivalents | 209,635 | 1,874,921 | (1,932,489) |
| Cash and cash equivalents at end of the year | 1,034,965 | 2,855,093 | 1,190,572 |
| Key indicators | |||
| Loss per share - Basic and diluted (RMB) | (6.22) | (9.48) | (0.67) |
| Current Ratio | 1.90 | 1.22 | 1.34 |
